Eli Lilly (LLY)

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what to expect. Amneal beat analys...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday after market hours. Here’s what to look for. Corcept be...

Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing.

Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be...

Eli Lilly stock is trading at a record high.

GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.

Should you buy these stocks, too?

Eli Lilly and Company (NYSE:LLY) raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound incretin medicines and continued growth across international markets. Chair and CEO Dave Ricks said

Revenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones.

Eli Lilly's business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate.

VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.

The company’s comeback strategy looks sound.

Revenue surged 39% on blockbuster obesity drug demand and strong international growth.

Eli Lilly’s realized prices fell 15%, but a 53% jump in volume pushed revenue up 39% and lifted full-year guidance by $5.5 billion. Here’s why the math works, and what could break it.

What happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 8.1% in the morning session after the company reported third-quarter 2026 ...

Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound.

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 38.6% year on year to...